Mandate

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors.

Oncopeptides is a biotech company focused on research and development of pharmaceuticals for difficult-to-treat haematological diseases. The Company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström (capital markets), and Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (financing).

Related

Vinge has assisted KMC Properties in its merger with Logistea

On June 14, 2024, KMC Properties ASA, listed on Oslo Børs, announced that the company is merging with Logistea AB (publ), listed on Nasdaq Stockholm.
June 24, 2024

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
June 20, 2024

Vinge advises Axcel VI and the Currentum in connection with the acquisition of Elektro-Emanuel

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elektro-Emanuel AB. The company carries out electrical installations for both companies and private individuals and has offices in four cities in western Sweden.
June 19, 2024